Navigation Links
Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
Date:1/28/2008

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Jan. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that, based on its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the Company plans to begin a pivotal confirmatory Phase 3 trial of Dimebon(TM) for mild-to-moderate Alzheimer's Disease in the second quarter of 2008.

The FDA informed Medivation that the company's previously completed trial conducted in Russia can be used as one of the two pivotal studies required to support the approval of Dimebon to treat mild-to-moderate Alzheimer's disease, as long as a significant proportion of the sites in the confirmatory Phase 3 trial are located in the United States.

"We are now a Phase 3 company with clear regulatory guidance on the pivotal trials required to seek marketing approval for Dimebon in the United States," said David T. Hung, M.D., president and chief executive officer of Medivation. "This is a significant step forward for Medivation, and validates our strategy to advance Dimebon directly into a pivotal Phase 3 trial."

The Phase 3 clinical trial will enroll approximately 525 patients with mild-to-moderate Alzheimer's disease at sites in the United States, Europe and South America. Patients will be randomized to one of three treatment groups: Dimebon 20 mg three times per day (TID); Dimebon 5 mg TID; and placebo. Patients will be treated for six months and may not be taking any other Alzheimer's disease drugs. The primary endpoints are the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change plus caregiver interview (CIBIC-plus).

In the previously com
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Health Plans Increase Use of Health Incentives
3. Area Health Care Providers Announce Plans to Integrate Services
4. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
5. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
6. Precedent Launches Revolutionary Individual Health Insurance Plans in Texas
7. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
8. CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans
9. Delta Dental Plans Association Forms National Scientific Advisory Committee
10. Health Care Service Corporation Provides Personal Clinical Summaries to Members of its Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas
11. Massachusetts Employers and Health Plans Continue to Support Quality Care by Rewarding Physicians through Bridges to Excellence Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
(Date:7/13/2014)... 13, 2014 Fadhits.com is popular among ... dresses are extremely beautiful. Recently, the company has announced ... for 2014. What’s more, all these outfits are available ... , Additionally, the supplier is now offering similar ... Quinceanera dresses, it has many other designs for sale, ...
(Date:7/13/2014)... A decreased ability to identify odors might ... disease, while examinations of the eye could indicate ... Alzheimer,s, in the brain, according to the results ... Alzheimer,s Association International Conference 2014 (AAIC 2014) in ... decreased ability to identify odors was significantly associated ...
(Date:7/13/2014)... 13, 2014 A Xarelto lawsuit ... LLC to provide consumers with the most current information ... of the blood-thinning medication, as well as the ... courts around the country. The law firm is now ... suffered from life-threatening internal bleeding and related complications while ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today ... at the Tamarack Senior Living Community in Palatine, IL. The ... on the 3rd Wednesdays of every month. This group ... Community located at 55 S. Greeley St. Palatine, IL 60067. ... is no cost for the group. , “A grief ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... Systems (TSX: LMZ,AMEX: LMZ), a healthcare technology company ... for obstetrics, today announced that its,Board of Directors ... from Amex., The decision is in keeping ... control costs in order to become cash flow,positive. ...
... Presentations highlight Palomid 529 as an inhibitor of macular ... ... JAMAICA PLAIN, Mass., May 1 Paloma Pharmaceuticals,Inc. today announced ... the Association for Research in Vision and Ophthalmology (ARVO),describing the ...
... The Cosmetic Bootcamp LLC,announced today that its summer ... According to Dr. Kenneth Beer, this year,s meeting is,expected ... meeting has,experienced since its inception four years ago. Dr. ... credibility the meeting has gained with both,physicians and industry. ...
... 1 Perrigo Company,(Nasdaq: PRGO ; TASE) ... a,quarterly dividend of $0.05 per share, payable on ... 25, 2008., Perrigo Company is a leading ... (OTC) and prescription,pharmaceuticals, nutritional products, active pharmaceutical ingredients,(API) ...
... MedCath Corporation,(Nasdaq: MDTH ) announced that its ... Securities 33rd Annual Health Care,Conference held May 5 - ... management will give its presentation on Wednesday,May 7 at ... live over the,Internet via MedCath,s website ( http://www.medcath.com ) ...
... increases 5 percent to $22.9 billion, - GAAP earnings from continuing operations reach $366 million from ... of $5 million in the prior-year period, - GAAP diluted earnings per share from ... from a loss of $0.01 in prior-year period, - Non-GAAP diluted EPS from ... ...
Cached Medicine News:Health News:LMS to delist from Amex 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 3Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 4Health News:Cardinal Health Reports Third Quarter Results 2Health News:Cardinal Health Reports Third Quarter Results 3Health News:Cardinal Health Reports Third Quarter Results 4Health News:Cardinal Health Reports Third Quarter Results 5Health News:Cardinal Health Reports Third Quarter Results 6Health News:Cardinal Health Reports Third Quarter Results 7Health News:Cardinal Health Reports Third Quarter Results 8Health News:Cardinal Health Reports Third Quarter Results 9Health News:Cardinal Health Reports Third Quarter Results 10Health News:Cardinal Health Reports Third Quarter Results 11Health News:Cardinal Health Reports Third Quarter Results 12Health News:Cardinal Health Reports Third Quarter Results 13Health News:Cardinal Health Reports Third Quarter Results 14Health News:Cardinal Health Reports Third Quarter Results 15Health News:Cardinal Health Reports Third Quarter Results 16Health News:Cardinal Health Reports Third Quarter Results 17Health News:Cardinal Health Reports Third Quarter Results 18Health News:Cardinal Health Reports Third Quarter Results 19Health News:Cardinal Health Reports Third Quarter Results 20Health News:Cardinal Health Reports Third Quarter Results 21Health News:Cardinal Health Reports Third Quarter Results 22Health News:Cardinal Health Reports Third Quarter Results 23Health News:Cardinal Health Reports Third Quarter Results 24Health News:Cardinal Health Reports Third Quarter Results 25Health News:Cardinal Health Reports Third Quarter Results 26Health News:Cardinal Health Reports Third Quarter Results 27Health News:Cardinal Health Reports Third Quarter Results 28Health News:Cardinal Health Reports Third Quarter Results 29Health News:Cardinal Health Reports Third Quarter Results 30Health News:Cardinal Health Reports Third Quarter Results 31
(Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Sigma-Aldrich Corporation (NASDAQ: SIAL ) will ... KeyBanc Capital Markets 2011 Basic Materials ... InterContinental, Boston, MA, presenting at 9:00 AM (Eastern). ... at the Grand Hyatt, New York, NY, presenting at ...
... SimonMed and Cox Business have partnered to make a ... patients in the Valley and across the state at ... is the first dedicated outpatient offering of breast tomosynthesis ... in Scottsdale. Sub-specialty trained radiologists at SimonMed ...
Cached Medicine Technology:Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences 2SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona 2
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: